Arca
Skip to content
Tools
Tools

SLC12A1: Solute carrier family 12 member 1

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Renal sodium, potassium and chloride non-electrogenic ion symporter that mediates the transepithelial NaCl reabsorption in the thick ascending limb and plays an essential role in the urinary concentration and volume regulation.

  • Drugs that act on it: 4
  • Approved: 4
  • In phases 1 to 3: 0
  • Sponsors: 3

Who Is On It, and How Far Along

Every drug ChEMBL records acting on SLC12A1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule

Approved4

  • Furosemide
  • Bumetanide
  • Torsemide
  • Ethacrynic acid

Phase 30

    Phase 20

      Phase 10

        Sponsors

        Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

        Modalities

        Drugs on this target by ChEMBL molecule type.

        • Small molecule4100%

        The Landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Sodium-(potassium)-chloride cotransporter 2 inhibitor.
        FurosemideApprovedValidus PharmaceuticalsSmall moleculeInhibitor—72Boxed warning
        BumetanideApprovedValidus PharmaceuticalsSmall moleculeInhibitor—12Boxed warning
        TorsemideApprovedPharmoBedientSmall moleculeInhibitor—3—
        Ethacrynic acidApprovedBausch HealthSmall moleculeInhibitor—2—

        Open Trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 19 in all, from ClinicalTrials.gov.
        Phase 0 Study to Define the Effect of Low Dose Ethacrynic Acid on Total Glutathione (GSH) Levels and Glutathione S-transferase (GST) ActivityEthacrynic acidEarly phase 1Not yet recruitingUniversity of Vermont Medical Center2026-11-17
        DESAL-HEART: Hypertonic Saline Added to a Pre-declared Furosemide Dose in Acute Heart FailureFurosemidePhase 4Not yet recruitingUniversity of Alberta2026-11-10
        Natriuresis With Acetazolamide or SGLT2 Inhibitors Added to Intravenous Loop Diuretics in Decompensated Heart FailureFurosemidePhase 4Active, not recruitingUniversidade do Porto2026-11-09
        Role of Postpartum Furosemide in Recovery of Patients With Severe PreeclampsiaFurosemideNot applicableRecruitingLady Reading Hospital, Pakistan2026-10-06
        A Comparative Study of Normalized Residual Activity and Standard Parameters in 99mTc-DTPA Diuretic Renography:Furosemide—Not yet recruitingAssiut University2026-09-10
        ACetazolamide in Patients With Heart Failure, to Decrease Weight and relIEVE Symptoms.FurosemidePhase 3Not yet recruitingUniversity Hospital, Montpellier2026-07-30
        The Impact of Intraoperative Diuretic Use on Delayed Graft Function Following Deceased Donor Renal TransplantationFurosemideNot applicableRecruitingLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's2026-07-24
        FST Analysis Supporting Timely Therapy and Risk Assessment Via Clinical Decision Support for KidsFurosemide—RecruitingChildren's Hospital Medical Center, Cincinnati2026-07-22
        "Exploring the Potential Benefits of Using Dapagliflozin in Cirrhotic Chronic Liver Disease Patients- A Randomized Controlled Trial"Furosemide, TorsemidePhase 2 / Phase 3RecruitingBeni-Suef University2026-07-06
        A Comparative Bioavailability Study of Two Torasemide 10 mg Tablets Formulations in Healthy Adult Participants Under Fasting Conditions:TorsemidePhase 1RecruitingBerlin-Chemie AG Menarini Group2025-10-01
        Bumetanide vs. Furosemide in CirrhosisBumetanidePhase 3RecruitingStacy Johnson2025-04-23
        Diuretic Testing in Chronic Kidney DiseaseBumetanideNot applicableRecruitingErasmus Medical Center2025-02-24
        Diuretics vs. Afterload Reduction for Treatment of HeartLogic AlertsBumetanide, TorsemidePhase 4RecruitingHeart Center Research, LLC2024-01-23
        Mechanisms of Diuretic Resistance in Heart Failure, Aim 3BumetanidePhase 1RecruitingYale University2024-01-17
        Bumetanide in Patients With Alzheimer's DiseaseBumetanidePhase 2RecruitingStanford University2023-09-25
        Mechanisms of Diuretic Resistance in Heart Failure, Aim 2BumetanidePhase 1RecruitingYale University2023-03-03
        Mechanisms of Diuretic Resistance in Heart Failure, Aim 1BumetanidePhase 1RecruitingYale University2022-04-12
        Role of Bumetanide in Treatment of AutismBumetanidePhase 3RecruitingSherief Abd-Elsalam2021-02-23
        Pharmacokinetics of Drugs Administered to ChildrenEthacrynic acid—RecruitingDuke University2018-03-29

        Diseases Most Associated With It

        Open Targets association score, 0 to 1; all associations
        Bartter disease type 1
        0.79
        Bartter syndrome
        0.72
        Hypertensive disorder
        0.62
        Congestive heart failure
        0.61
        Cirrhosis of liver
        0.60
        Kidney disorder
        0.60
        Cardiovascular disorder
        0.54
        Pulmonary edema
        0.51
        Hereditary disease
        0.48

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1874, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q13621, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.